1. Long-term Outcome of Perianal Fistulizing Crohn's Disease Treated With Infliximab 
Guillaume Bouguen, Laurent Siproudhis, Emmanuel Gizard, Timothée Wallenhorst, Vincent Billioud, Jean–François Bretagne, Marc– André Bigard, Laurent Peyrin–Biroulet 
Clinical Gastroenterology and Hepatology 
Volume 11, Issue 8, Pages e4 (August 2013)
DOI: /j.cgh
Copyright © 2013 AGA Institute Terms and Conditions

2. Figure 1 Flow chart of the 156 patients.
Clinical Gastroenterology and Hepatology  , e4DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

3. Figure 2 Cumulative probability of first fistula closure.
Clinical Gastroenterology and Hepatology  , e4DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

4. Figure 3
Kaplan–Meier analysis of first fistula closure after IFX therapy initiation according to predictors identified by multivariate analysis. (A) Ileocolonic disease (L3). (B) Seton drainage duration. (C) Long-term treatment with IFX more than 118 weeks. (D) Combination therapy for immunosuppressant-naive patients.
Clinical Gastroenterology and Hepatology  , e4DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

5. Figure 4
Cumulative probability of fistula recurrence among the 108 patients who experienced fistula closure.
Clinical Gastroenterology and Hepatology  , e4DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

6. Supplementary Figure 1
Kaplan–Meier analysis of sustained fistula closure after IFX initiation according to predictors identified by multivariate analysis.
Clinical Gastroenterology and Hepatology  , e4DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions